WINONA STATE UNIVERSITY
UNDERGRADUATE STUDENT RESEARCH & CREATIVE PROJECTS FINAL REPORT
Electronically submit complete final report ten (10) days following completion of project to Grants & Sponsored Projects (grants@winona.edu).
Hover over fill-able fields for additional guideline and completion information.
Student Name:

Nawon Lee

Student Major:

BIOLOGY: ALLIED HEALTH

Faculty Sponsor:

Dr. Myoung E. Lee

Title of Project:

Student Email:

nlee16@winona.edu

Faculty Sponsor Email:

mlee@winona.edu

The Potential of Curcumin as Antioxidant for Diabetic Cataract Prevention

Project Abstract:

The student-authored final report MUST include each of the following (check boxes to verify inclusion of each component):
✔

This report form, fully completed (page 1 of this form)

✔

A copy of the project end product, appropriate to the standards of the discipline

Nawon Lee

Date:

Applicant Signature:

Date:
Faculty Sponsor Signature:

Submit complete reports electronically to Grants & Sponsored Projects (grants@winona.edu).
A deans' sub-committee makes decisions on Undergraduate Student Research & Creative Projects proposals.
Note that a copy of the project end product will be forwarded to Krueger Library for archival purposes.

04/26/2019

Nawon Lee Research Grant/Capstone Project Final Paper
Title
The Potential of Curcumin as Antioxidant for Diabetic Cataract Prevention
Abstract
Curcumin’s role as an antioxidant has been studied in numerous studies and has shown
potentials as a glycation inhibitor. This study aimed to study curcumin’s ability to inhibit glycation
of α-crystallin to find out its potentials as an antioxidant for preventing diabetic cataract. The first
experiment looked at the difference between the sample containing curcumin and the sample
without curcumin without any incubation period. The fluorescence detection was set at at 37
degrees Celsius for wavelengths of 325/434 nm, 295/340 nm, 330/415 nm and 370/440 nm
measuring for N-formylkynurenine, tryptophan, dityrosine and MGO respectively. There was no
significant difference between the sample containing curcumin and the sample without
curcumin. The results were the same in the experiment set at same conditions but with 24-hours
incubation period. The control experiment which was done in the same conditions except with a
known glycation inhibitor, aminoguanidine hydrochloride. With aminoguanidine hydrochloride,
there was a significant decrease in the fluorescence compared to its absence. Although there
were no experiments directly with α-crystallin, the test-run experiments with curcumin and
aminoguanidine hydrochloride provides evidence that curcumin failed to inhibit glycation of BSA
and has low probability with successful inhibition of α-crystallin glycation.

Introduction
Advanced glycation end products are the result of protein glycation and often lead to
development of several complications in diabetic patients. Early onset of cataracts is one of
many complications involved.1 The development of cataracts is common in people of age 65 or

older but diabetes can hasten the process through glycation of lens proteins.2 When cataracts
develop and begin to disrupt eyesight, most people residing in United States can easily remove
it through surgery since cataract surgery is one of the most common surgery in US with an
overall success rate of 98% or higher.3 However, many people in developing countries still
cannot afford cataract surgery and live with the discomfort until blindness sets on because there
are no medications available for the disease. To find an alternative to surgery for treating
cataracts, many different methods have been studied. Among several potential treatment
methods, antioxidants that inhibit advanced glycation end products have been studied as a way
to prevent cataracts. Although this is only preventive, it may still be helpful for diabetic patients
who do not expect to get the surgery to delay the early onset of cataracts. In this research,
curcumin, an antioxidant, will be studied for its effectiveness in preventing development of
cataracts due to advanced glycation.
Aggregation of advanced glycation end products is stimulated by oxidative stress and
hyperglycemia with diabetes and this aggregation of advanced glycation end products is what
leads to complications such as cataracts. Curcumin has been studied in the past with diabetic
rats for the relationship it may have with the advanced glycation end product levels. The study
showed that the oxidative stress and cross-linking of collagen decreased and glycation was
prevented in these diabetic rats.4 In this study, the focus is put on the glycation of lens crystallin
and the role of curcumin as an antioxidant to inhibit the glycation of this protein found in the eye
that leads to diabetic cataracts.
Figure 1: Structure of curcumin

Specifically, the glycation of α-crystallin found in the lens is common because α-crystallin
has a relatively long half-life and hence more prone to posttranslational modifications such as
glycation.5 Glycation of α-crystallin results in several problems as it loses its anti-apoptotic
activities and its function as chaperone protein leading to other protein aggregates.6 Curcumin
which has been found to reduce glycation in diabetic rats will be used with of α-crystallin and
D-glucose to measure its effectiveness in inhibiting glycation of lens crystallin to prevent
cataracts.
As a control experiment, aminoguanidine hydrochloride will be used in place of
curcumin. Aminoguanidine hydrochloride is a known glycation inhibitor due to its ability to lower
the effective concentration of glucose or MGO to slow down the glycation. Trial experiments will
first be conducted with bovine serum albumin (BSA) instead of α-crystallin. This is done to attain
the correct experimental parameters for α-crystallin and prevent wasting the limited resources.
In addition, as an alternative for when D-glucose is not significantly glycated in a given
amount of time, MGO will be used to replace it. MGO is a more powerful glycating agent than
glucose.
Figure 2: Structure of aminoguanidine hydrochloride

Figure 3: Structure of D-glucose

Figure 4: Structure of MGO (Methylglyoxal)

Materials and Methods
Curcumin from Curcuma longa (Turmeric), MGO, BSA and DMSO were the main materials used
in determining the influence of curcumin in inhibiting glycation. All materials were purchased
from Sigma Aldrich. To create an MGO solution with a concentration of 50mM, 77 µL of
filter-sterilized MGO was mixed with 10 mL of PBS (pH 7.4) which acted as a buffer. For the
protein solution with a concentration of 5 mg/mL, 50 mg of BSA was mixed in 10 mL of buffer.
Lastly, 0.0037g of curcumin was mixed with 1 mL of DMSO before adding 0.1 mL of this
solution to 29.9 mL of buffer to create a concentration of 0.05 mM. The purpose of mixing
curcumin with DMSO first was to aid in better resolution of curcumin in buffer. Different

combinations of these prepared solutions were pipetted into the microplate to create 6 controls
and 1 experimental condition. For the experimental solution, 0.1 mL of MGO, 0.1 mL of BSA
and 0.01 mL of curcumin was pipetted into each well in triplicates. The rest of the 6 control
samples were missing either BSA, curcumin, MGO, both BSA and MGO, both BSA and
curcumin or all BSA, MGO and curcumin. All the controls were pipetted in triplicates. In the first
experiment, the samples were incubated for 24 hours at 21 degrees Celsius and the incubation
was excluded in the second experiment. To read and measure glycation-related chemical and
conformational changes, the microplate reader was set at 37 degrees Celsius for 325/434 nm
(N-formylkynurenine), 295/340 nm (Tryptophan), 330/415 nm (Dityronsine) and 370/440 nm
(formation of advanced glycation end product). To test what effects were brought by curcumin,
all conditions were kept the same in the third experiment with 1 mM of aminoguanidine
hydrochloride replacing the curcumin solution. Aminoguanidine hydrochloride is a known
glycation inhibitor.
Results and Discussion
Graph 1: Glycation progression without incubation in the presence of curcumin measured at
370/440 nm.

Graph 2: Glycation progression without incubation in the presence of curcumin measured at
325/434 nm.

Graph 3: Glycation progression without incubation in the presence of curcumin measured at
295/340 nm.

Graph 4: Glycation progression without incubation in the presence of curcumin measured at
330/415 nm.

Graph 5: Glycation progression after incubation in the presence of curcumin measured at
370/440 nm.

Graph 6: Glycation progression after incubation in the presence of curcumin measured at
325/434 nm.

Graph 7: Glycation progression after incubation in the presence of curcumin measured at
295/340 nm.

Graph 8: Glycation progression after incubation in the presence of curcumin measured at
330/415 nm.

Graph 9: Glycation progression after incubation in the presence of aminoguanidine
hydrochloride measured at 370/440 nm.

Graph 10: Glycation progression after incubation in the presence of aminoguanidine
hydrochloride measured at 325/434 nm.

Graph 11: Glycation progression after incubation in the presence of aminoguanidine
hydrochloride measured at 295/340 nm.

Graph 12: Glycation progression after incubation in the presence of aminoguanidine
hydrochloride measured at 330/415 nm.

The initial design for this research was to find the glycation inhibition potential of
curcumin with α-crystallin. The first few experiments with BSA was going to be test runs to find
out the optimal concentration, incubation period and wavelength for the experiment with
α-crystallin. However, these experiments with BSA failed to demonstrate curcumin as a
glycation inhibitor.
Graphs 1, 2, 3, 4 show insignificant difference in the rate of AGE production between the
experimental sample containing all MGO, BSA and curcumin and the control sample containing
just MGO and BSA. As graphs 5, 6, 7, 8 indicate, a 24 hour incubation period did not make
much difference between the control and experimental samples. Still, a 24 hour incubation
seem to be effective with detecting a more stable glycation progression as illustrated by the
relatively constant fluorescence in graphs 5, 6, 7, 8 compared to graphs 1, 2, 3, 4.

The control experiment with a known glycation inhibitor, aminoguanidine hydrochloride,
shows a significant difference in the rate of AGE production between the experimental and
control samples. Graphs 9, 10, 11, 12 show a significantly lower fluorescence at every
wavelength for the sample containing aminoguanidine hydrochloride compared to the sample
not containing it. This control experiment supports the failure of inhibiting glycation with
curcumin in the previous experiments.

Conclusion
This series of experiments failed to support or reject the hypothesis that curcumin
inhibits the glycation of α-crystallin. This is because there were no actual experiments with
curcumin and α-crystallin to draw conclusions from. However, experiments with curcumin and
BSA which were supposed to be test-runs provided enough evidence that there is a low
probability that curcumin will prevent glycation of α-crystallin. There were no significant
decrease in the fluorescence for the sample containing curcumin compared to the sample
without curcumin. The results remained unchanged even after a 24 hour incubation.
The experiment under same conditions with aminoguanidine hydrochloride as the
glycation inhibitor showed a significant decrease in the fluorescence for the sample containing
aminoguanidine hydrochloride compared to the sample without it. This helped determine that it
was curcumin that failed to cause decrease AGE production.
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